The Technical Analyst
Kinnate Biopharma Inc. [KNTE]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Kinnate Biopharma Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.00% $2.65
America/New_York / 2 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 124.99 mill |
| EPS: | -2.78 |
| P/E: | -0.950 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 47.17 mill |
| Avg Daily Volume: | 0.418 mill |
| RATING 2024-04-03 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.950 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.16x |
| Company: PE -0.950 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.156 (-56.39%) $-1.494 |
| Date: 2024-04-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 2.58 - 2.72 ( +/- 2.79%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-03 | Tananbaum James B. | Sell | 520 711 | Common Stock |
| 2024-04-03 | Tananbaum James B. | Sell | 40 501 | Stock Option (right to buy) |
| 2024-04-03 | Tananbaum James B. | Sell | 20 250 | Stock Option (right to buy) |
| 2024-04-03 | Farzan Nima | Sell | 2 186 | Common Stock |
| 2024-04-03 | Farzan Nima | Sell | 1 281 642 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| -20.92 |
| Last 99 transactions |
| Buy: 9 508 542 | Sell: 7 832 534 |
Forecast:
16:00 - $2.66
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $2.66
Forecast 2: 16:00 - $2.66
Forecast 3: 16:00 - $2.66
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.65 (0.00% ) |
| Volume | 2.12 mill |
| Avg. Vol. | 0.418 mill |
| % of Avg. Vol | 508.07 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For KNTE
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.33 | N/A | Active |
|---|
KNTE
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Latest Press Releases
2024-03-13 11:49:00 - Press Release
Kinnate Biopharma Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Kinnate Biopharma Inc. - Knte
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of kinnate biopharma inc. (nasdaqgs: knte) to xoma corporation (nasdaqgm: xoma). under the terms of the proposed transaction, shareholders of hireright will receive (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a.
2024-03-01 08:35:00 - Press Release
Kinnate Biopharma Inc. Sells Its Investigational Pan-raf Inhibitor, Exarafenib, To Pierre Fabre Laboratories
Kinnate has entered into an asset purchase agreement (the "apa") with pierre fabre laboratories for global rights to exarafenib and other pan-raf program assets. the transaction is in furtherance of kinnate's previously announced pursuit of strategic alternatives.
2024-03-01 08:30:00 - Press Release
Kinnate Biopharma Inc. Sells Its Investigational Pan-raf Inhibitor, Exarafenib, To Pierre Fabre Laboratories
San francisco, san diego and castres, france, march 01, 2024 (globe newswire) -- kinnate biopharma inc. (nasdaq: knte) (“kinnate” or the “company”), a clinical-stage precision oncology company, and pierre fabre mÉdicament, sas (“pierre fabre laboratories”), a global player in oncology, today announced their agreement to the sale of the company's investigational pan-raf inhibitor, exarafenib, and other pan-raf program assets pursuant to the apa entered into by the parties. the sale of global rights is in furtherance of the company's previously announced exploration of strategic alternatives.
2024-02-19 11:03:00 - Press Release
Kinnate Biopharma Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Kinnate Biopharma Inc. - Knte
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of kinnate biopharma inc. (nasdaqgs: knte) to xoma corporation (nasdaqgm: xoma). under the terms of the proposed transaction, shareholders of hireright will receive (i) a base cash price of $2.3352 per share and (ii) an additional cash amount of not more than $0.2527 per share at the closing of the merger plus a.
2024-02-16 17:57:00 - Press Release
Alert: Rowley Law Pllc Is Investigating Proposed Acquisition Of Kinnate Biopharma Inc.
New york , feb. 16, 2024 /prnewswire/ -- rowley law pllc is investigating potential securities law violations by kinnate biopharma inc. (nasdaq: knte) and its board of directors concerning the proposed acquisition of the company by xoma corporation. stockholders will receive between $2.3352 and $2.5879, as well as one contingent value right, for each share of kinnate biopharma stock that they hold.
Latest News
2024-02-28 13:01:20 - Zacks Investment Research
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock?
Kinnate Biopharma Inc. (KNTE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
2023-10-03 11:16:07 - Zacks Investment Research
Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why
Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.
2023-06-01 16:05:00 - GlobeNewsWire
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
SAN FRANCISCO and SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will participate in two upcoming investor conferences:
2023-05-07 12:50:26 - InvestorPlace
7 Stocks With Promising Upside Potential for 100% Returns
While your friendly financial advisor will probably never recommend these terribly risky enterprises, sometimes, you're just in the mood for stocks with 100% upside potential. And with these ideas, you're going to get that and more, assuming the stars align correctly.
2023-05-03 13:00:53 - PennyStocks
4 Penny Stocks To Buy According To Insiders This Quarter
Insiders think these are penny stocks to buy based on recent filings but are they worth the risk? The post 4 Penny Stocks To Buy According To Insiders This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2023-03-14 18:09:00 - GlobeNewsWire
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that a clinical trial abstract for its investigational pan-RAF inhibitor exarafenib has been selected for an oral presentation during the Clinical Trials Mini Symposium Session at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19 in Orlando, Fla.
2023-01-17 16:05:00 - GlobeNewsWire
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822) evaluating the Company's investigational pan-FGFR inhibitor, KIN-3248, at two upcoming American Society of Clinical Oncology (ASCO)-related conferences.
2022-10-11 13:32:29 - Zacks Investment Research
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: Here's What You Should Know
Kinnate Biopharma Inc. (KNTE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-06-01 16:05:00 - GlobeNewsWire
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will participate in two upcoming in-person investor conferences:
2022-05-26 17:00:00 - GlobeNewsWire
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
Preclinical data from a study of the Company's pan-RAF product candidate, KIN-2787, in combination with MEK inhibitor, also accepted for publication in the meeting proceedings Preclinical data from a study of the Company's pan-RAF product candidate, KIN-2787, in combination with MEK inhibitor, also accepted for publication in the meeting proceedings